Recent studies have identified an aberrant myeloid cell activation programme in patients with COVID-19. In this preprint, Hoepel et al. elucidate a mechanism by which alveolar macrophages facilitate hyperinflammation. Serum IgGs, in complex with spike protein, from patients with severe COVID-19 were shown to induce a potent pro-inflammatory response in human macrophages through multiple FcγRs, but mainly through FcγRII. Blockade of this pathway using an inhibitor of the kinase SYK counteracted the pathological production of IL-6, IL-1β and TNF. Interestingly, in vitro exposure of endothelial cells to serum IgGs from these patients resulted in loss of barrier integrity and increased coagulopathy. These results improve our understanding of the abnormal myeloid response in COVID-19 and identify a potential therapeutic target.
References
Original article
Hoepel, W. et al. Anti-SARS-CoV-2 IgG from severely ill COVID-19 patients promotes macrophage hyper-inflammatory responses. Preprint at bioRxiv https://doi.org/10.1101/2020.07.13.190140 (2020)
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The author declares no competing interests.
Rights and permissions
About this article
Cite this article
Park, M.D. IgGs drive COVID-19 myeloid hyperinflammation. Nat Rev Immunol 20, 521 (2020). https://doi.org/10.1038/s41577-020-00415-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41577-020-00415-9
This article is cited by
-
NF-κB signalling as a pharmacological target in COVID-19: potential roles for IKKβ inhibitors
Naunyn-Schmiedeberg's Archives of Pharmacology (2021)